TNF-blockade in patients with advanced hormone refractory prostate cancer

被引：5
作者：
Diaz, Luis A., Jr. [1 ,2 ]
Messersmith, Wells [3 ]
Sokoll, Lori [2 ,4 ]
Sinibaldi, Vicki [2 ]
Moore, Sandy [2 ]
Carducci, Michael [2 ]
Eisenberger, Mario [2 ]
机构：
[1] Ludwig Ctr Canc Genet & Therapeut Johns Hopkins, Baltimore, MD 21231 USA
[2] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA
[3] Univ Colorado, Div Med Oncol, Ctr Canc, Aurora, CO 80045 USA
[4] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA
来源：
INVESTIGATIONAL NEW DRUGS | 2011年 / 29卷 / 01期
关键词：
Prostate cancer; Hormone refractory; TNF-alpha; Infliximab; IL-6; INTERLEUKIN-6; PATHWAY; GROWTH;
D O I：
10.1007/s10637-009-9346-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：192 / 194
页数：3
相关论文
共 50 条
  • [11] CI-980 in Advanced Melanoma and Hormone Refractory Prostate Cancer
    Christopher W. Ryan
    Keith L. Shulman
    Jon M. Richards
    John W. Kugler
    Jeffrey A. Sosman
    Rafat H. Ansari
    Everett E. Vokes
    Nicholas J. Vogelzang
    Investigational New Drugs, 2000, 18 : 187 - 191
  • [12] Pathogenesis of prostate cancer and hormone refractory prostate cancer
    Girling, J. S.
    Whitaker, H. C.
    Mills, I. G.
    Neal, D. E.
    INDIAN JOURNAL OF UROLOGY, 2007, 23 (01) : 35 - 42
  • [13] The biology of hormone refractory breast and prostate cancer An NCI workshop report
    Mohla, Suresh
    Stearns, Vered
    Sathyamoorthy, Neeraja
    Rosenfeld, Michael G.
    Nelson, Peter
    CANCER BIOLOGY & THERAPY, 2009, 8 (21) : 1975 - 1985
  • [14] Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer
    Drachenberg, DE
    Elgamal, AAA
    Rowbotham, R
    Peterson, M
    Murphy, GP
    PROSTATE, 1999, 41 (02) : 127 - 133
  • [15] Current strategies in the management of hormone refractory prostate cancer
    Martel, CL
    Gumerlock, PH
    Meyers, FJ
    Lara, PN
    CANCER TREATMENT REVIEWS, 2003, 29 (03) : 171 - 187
  • [16] Treatment with prednisolone of hormone-refractory prostate cancer
    Fuse, H
    Nozaki, T
    Fujiuchi, Y
    Mizuno, I
    Nagakawa, O
    Okumura, A
    ARCHIVES OF ANDROLOGY, 2006, 52 (01): : 35 - 38
  • [17] Octreotide in the management of hormone-refractory prostate cancer
    Vainas, IG
    CHEMOTHERAPY, 2001, 47 : 109 - 126
  • [18] Current strategies in the management of hormone refractory prostate cancer
    Martel, CL
    Gumerlock, PH
    Meyers, FJ
    Lara, PN
    ANNALES D UROLOGIE, 2004, 38 (03) : 85 - 102
  • [19] Hormone-Refractory prostate cancer
    Rini B.I.
    Small E.J.
    Current Treatment Options in Oncology, 2002, 3 (5) : 437 - 446
  • [20] The management of hormone refractory prostate cancer
    Newling, DWW
    EUROPEAN UROLOGY, 1996, 29 : 69 - 74
12345